nach oben

Breast Cancer Research and Treatment

Erschienen in:

02.12.2016 | Preclinical Study

Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status

verfasst von: Yul Ri Chung, Hyun Jeong Kim, Min Hye Jang, So Yeon Park

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Interaction between immune-regulatory proteins and tumor infiltrating lymphocytes (TILs) is complex, and their associations may have significant clinical implications. This study was designed to evaluate the relationships between immunomodulatory proteins and TIL subsets and their impact on prognosis in breast cancer.

Methods

377 invasive breast cancer cases were selected, and immunohistochemistry was performed for HLA-A, HLA-ABC, and indoleamine 2,3-dioxygenase (IDO); CD4+, CD8+, and FOXP3+ T cells were counted in intratumoral and stromal areas for both absolute numbers as well as their ratios.

Results

While HLA-ABC and HLA-A expressions showed a positive correlation with CD8+ and FOXP3+ TIL infiltration, IDO expression showed a negative correlation with FOXP3+/CD4+ and FOXP3+/CD8+ T cell ratios. Expressions of HLA-ABC, HLA-A, and IDO shared an association with negative estrogen receptor status. Infiltration of CD4+, CD8+, and FOXP3+ TILs was significantly higher in tumors with high histologic grade, negative hormone receptor status, HER2 amplification, high Ki-67 index, and p53 overexpression. In survival analyses, increased CD4+ TIL infiltration was associated with better prognosis of the patients while other TIL subset infiltration and expression of immunomodulatory proteins had no prognostic significance. In subgroup analyses, high CD4+ TIL infiltration was revealed as an independent good prognostic factor in hormone receptor-negative subgroup while high FOXP3+/CD8+ T cell ratio was found to be an independent adverse prognostic factor in hormone receptor-positive subgroup, especially in luminal A subtype.

Conclusion

CD4+ TIL subset and FOXP3+/CD8+ T cell ratio have different prognostic significance in breast cancer according to hormone receptor status.

Bindea G, Mlecnik B, Fridman WH, Galon J (2011) The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 33(4):335–340. doi:10.1007/s00281-011-0264-x CrossRefPubMedPubMedCentral

DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9(4):212. doi:10.1186/bcr1746 CrossRefPubMedPubMedCentral

Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269–1274. doi:10.1038/nm934 CrossRefPubMed

Powell AG, Horgan PG, Edwards J (2012) The bodies fight against cancer: is human leukocyte antigen (HLA) class 1 the key? J Cancer Res Clin Oncol 138(5):723–728. doi:10.1007/s00432-012-1192-4 CrossRefPubMed

Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K, Solbach C, Schrader I, Dietel M, von Minckwitz G (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(1):105–113. doi:10.1200/JCO.2009.23.7370 CrossRefPubMed

Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JP, Hitre E, de Azambuja E, Quinaux E, Di Leo A, Michiels S, Piccart MJ, Sotiriou C (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31(7):860–867. doi:10.1200/JCO.2011.41.0902 CrossRefPubMed

Mohammed ZMA, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC (2012) The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer 107(5):864–873. doi:10.1038/bjc.2012.347 CrossRefPubMedPubMedCentral

Lee HJ, Seo JY, Ahn JH, Ahn SH, Gong G (2013) Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer 16(1):32–39. doi:10.4048/jbc.2013.16.1.32 CrossRefPubMedPubMedCentral

Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, Ellis IO, Green AR (2011) Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29(15):1949–1955. doi:10.1200/JCO.2010.30.5037 CrossRefPubMed

10.

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart MJ, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25(8):1544–1550. doi:10.1093/annonc/mdu112 CrossRefPubMed

11.

Ibrahim EM, Al-Foheidi ME, Al-Mansour MM, Kazkaz GA (2014) The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 148(3):467–476. doi:10.1007/s10549-014-3185-2 CrossRefPubMed

12.

Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380. doi:10.1200/Jco.2006.05.9584 CrossRefPubMed

13.

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, Veys I, Haibe-Kains B, Singhal SK, Michiels S, Rothe F, Salgado R, Duvillier H, Ignatiadis M, Desmedt C, Bron D, Larsimont D, Piccart M, Sotiriou C, Willard-Gallo K (2013) CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Investig 123(7):2873–2892. doi:10.1172/JCI67428 CrossRefPubMedPubMedCentral

14.

Milani A, Sangiolo D, Montemurro F, Aglietta M, Valabrega G (2013) Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 24(7):1740–1748. doi:10.1093/annonc/mdt133 CrossRefPubMed

15.

Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: summary of the consensus discussion. Breast Care 6(2):136–141. doi:10.1159/000328054 (Basel) CrossRefPubMedPubMedCentral

16.

Seo AN, Lee HJ, Kim EJ, Kim HJ, Jang MH, Lee HE, Kim YJ, Kim JH, Park SY (2013) Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer 109(10):2705–2713. doi:10.1038/bjc.2013.634 CrossRefPubMedPubMedCentral

17.

Bos R, Sherman LA (2010) CD4(+) T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8(+) T lymphocytes. Cancer Res 70(21):8368–8377. doi:10.1158/0008-5472.Can-10-1322 CrossRefPubMedPubMedCentral

18.

Zamarron BF, Chen WJ (2011) Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 7(5):651–658CrossRefPubMedPubMedCentral

19.

Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, Shin SW, Kim YH, Kim JS, Park KH (2013) Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 36(3):224–231. doi:10.1097/COC.0b013e3182467d90 CrossRefPubMed

20.

Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63(1):67–72. doi:10.1007/s00262-013-1490-y CrossRefPubMed

21.

Shou J, Zhang Z, Lai Y, Chen Z, Huang J (2016) Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic review and meta-analysis. BMC Cancer 16:687. doi:10.1186/s12885-016-2732-0 CrossRefPubMedPubMedCentral

22.

Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO (2014) Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 16(5):432. doi:10.1186/s13058-014-0432-8 CrossRefPubMedPubMedCentral

23.

Loi S (2013) Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology 2(7):e24720. doi:10.4161/onci.24720 CrossRefPubMedPubMedCentral

24.

Fleming KA, McMichael A, Morton JA, Woods J, McGee JO (1981) Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer. J Clin Pathol 34(7):779–784CrossRefPubMedPubMedCentral

25.

Lee HJ, Song IH, Park IA, Heo SH, Kim YA, Ahn JH, Gong G (2016) Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling. Oncotarget. doi:10.18632/oncotarget.8798

26.

Ryu YH, Kim JC (2007) Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Investig Ophthalmol Vis Sci 48(9):4148–4152. doi:10.1167/iovs.05-1336 CrossRef

27.

Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A (2006) Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 12(4):1144–1151. doi:10.1158/1078-0432.CCR-05-1966 CrossRefPubMed

28.

Inaba T, Ino K, Kajiyama H, Yamamoto E, Shibata K, Nawa A, Nagasaka T, Akimoto H, Takikawa O, Kikkawa F (2009) Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma. Gynecol Oncol 115(2):185–192. doi:10.1016/j.ygyno.2009.07.015 CrossRefPubMed

29.

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, Isobe K, Kikkawa F (2008) Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14(22):7251–7259. doi:10.1158/1078-0432.CCR-08-0991 CrossRefPubMed

30.

Laimer K, Troester B, Kloss F, Schafer G, Obrist P, Perathoner A, Laimer J, Brandacher G, Rasse M, Margreiter R, Amberger A (2011) Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas. Oral Oncol 47(5):352–357. doi:10.1016/j.oraloncology.2011.03.007 CrossRefPubMed

31.

Ivan H, Chan VW, Bilardello Melissa, Jorgenson Brett, Bal Harminder, McCauley Scott, Van Vlasselaer Peter, Mumm JB (2016) PEG-rIL-10 treatment decreases FoxP3+ Tregs despite upregulation of intratumoral IDO. Oncoimmunology 5(7):e1197458. doi:10.1080/2162402X.2016.1197458 CrossRef

32.

Larrain MTI, Rabassa ME, Lacunza E, Barbera A, Creton A, Segal-Eiras A, Croce MV (2014) IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis. Tumor Biol 35(7):6511–6519. doi:10.1007/s13277-014-1859-3 CrossRef

33.

Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S (2013) Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry. Cancer Immunol Immun 62(5):829–837. doi:10.1007/s00262-013-1393-y CrossRef

Titel: Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status
verfasst von: Yul Ri Chung
Hyun Jeong Kim
Min Hye Jang
So Yeon Park
Publikationsdatum: 02.12.2016
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-4072-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

Estimating the OncotypeDX score: validation of an inexpensive estimation tool

Does the TNM classification of solitary internal mammary lymph node metastases in breast cancer still apply?

Association between adjuvant chemotherapy and risk of acute kidney injury in elderly women diagnosed with early-stage breast cancer

Effects of exercise intervention in breast cancer patients: is mobile health (mHealth) with pedometer more effective than conventional program using brochure?

Aspirin/antiplatelet agent use improves disease-free survival and reduces the risk of distant metastases in Stage II and III triple-negative breast cancer patients

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie